210 related articles for article (PubMed ID: 32907756)
1. Immune response at 12-23 months following a single dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
Krow-Lucal ER; Laven J; Perry L; Biggerstaff BJ; Johnson BW; Hollis E; Fischer M; Woolpert T; Hills SL
Vaccine; 2020 Oct; 38(44):6899-6903. PubMed ID: 32907756
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
5. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
[TBL] [Abstract][Full Text] [Related]
9. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
10. Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019.
Seshadri S; Martin SW; Hills SL; Collins LC
Vaccine; 2023 Feb; 41(9):1537-1540. PubMed ID: 36725428
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
Assawawiroonhakarn S; Apiwattanakul N; Pakakasama S; Hongeng S; Anurathapan U; Yoksan S; Klinmalai C; Sae-Chew P; Techasaensiri C
Pediatr Infect Dis J; 2021 Mar; 40(3):264-268. PubMed ID: 33427799
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
13. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices.
Hills SL; Walter EB; Atmar RL; Fischer M;
MMWR Recomm Rep; 2019 Jul; 68(2):1-33. PubMed ID: 31518342
[TBL] [Abstract][Full Text] [Related]
14. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
Rabe IB; Miller ER; Fischer M; Hills SL
Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
[TBL] [Abstract][Full Text] [Related]
15. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
[TBL] [Abstract][Full Text] [Related]
16. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
19. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
Erra EO; Kantele A
Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
[TBL] [Abstract][Full Text] [Related]
20. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]